Financial Performance - Operating revenue surged by 172.69% to CNY 51,632,742.35 from CNY 18,934,728.57 in the same period last year[6] - Net profit attributable to shareholders reached CNY 5,579,552.35, a significant recovery from a loss of CNY 8,355,932.20 in the previous year[6] - Cash flow from operating activities improved to CNY 7,002,165.63, compared to a negative cash flow of CNY -5,839,970.38 in the same period last year[6] - Basic and diluted earnings per share were both CNY 0.11, recovering from a loss of CNY -0.11 per share in the previous year[6] - Operating profit reached CNY 10,382,528.60, a significant improvement from a loss of CNY 8,850,513.90 in the previous year[15] - Net profit for the period was CNY 8,770,089.85, compared to a loss of CNY 6,917,137.68 in the same period last year[15] - The gross profit for Q1 2018 was CNY 8,338,964.44, compared to CNY -9,885,519.22 in Q1 2017, showing a turnaround in profitability[25] - The total profit for Q1 2018 was CNY 3,796,779.04, compared to a loss of CNY 5,097,331.22 in the same period last year, showcasing a strong recovery in financial performance[27] Shareholder Information - The total number of shareholders reached 8,626 by the end of the reporting period[11] - The largest shareholder, Feng Yuxia, holds 28.56% of the shares, with a total of 23,359,500 shares, of which 10,180,000 are pledged[11] Asset and Liability Changes - Total assets increased by 4.03% to CNY 978,805,027 compared to the end of the previous year[6] - The total liabilities as of March 31, 2018, were CNY 436,387,154.50, an increase from CNY 383,084,840.96 at the beginning of the year, reflecting a growth of approximately 14%[20] - The total equity attributable to shareholders decreased to CNY 542,066,199.70 from CNY 557,436,824.30, reflecting a decrease of approximately 3%[20] Cash Flow Analysis - Cash inflows from operating activities totaled CNY 89,128,667.67, up from CNY 56,973,203.65 in the previous year, reflecting strong operational cash generation[31] - The net cash flow from operating activities was 7,002,165.63 RMB, a significant improvement compared to the previous year's negative cash flow of -5,839,970.38 RMB[32] - The net cash flow from financing activities was 9,597,090.00 RMB, an increase from 6,691,061.04 RMB in the previous year[33] Other Financial Metrics - The company reported non-recurring gains of CNY 3,191,358.20, which included government subsidies and other income[8] - The company's cash and cash equivalents decreased to CNY 245,383,740.84 from CNY 260,470,057.10, a decline of approximately 6%[21] - The company incurred management expenses of CNY 8,521,343.12, slightly down from CNY 9,339,573.50 in the previous year, indicating improved cost management[27] - The company recorded other income of CNY 488,747.88 in Q1 2018, down from CNY 766,223.72 in the same period last year[27] Market Strategy - The company has a strong focus on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[6] - The report indicates a commitment to maintaining financial transparency and accuracy, with all board members present for the review[6]
昭衍新药(603127) - 2018 Q1 - 季度财报